Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

• Status: Completed
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Diagnosis of probable AD according to the NINCDS-ADRDA criteria.

• Men and postmenopausal or surgically sterile women aged from 50 to 85 inclusive.

• Able to give informed consent. Patient's caregiver must consent to participate in the study.

Exclusion Criteria:

• Significant neurologic disease other than AD that may affect cognition.

• Current clinically significant systemic illness which is likely to deteriorate or affect the subject's safety during the study.

Other exclusions apply